Summit Therapeutics Inc. (NASDAQ: SMMT) is a Healthcare company (Biotechnology) with a market capitalization of $12.0B. The Maz Rating grades it against the other companies in its sector.
About three months ago (July 2, 2026), Summit Therapeutics Inc. had a Maz Rating of 1.21 out of 5 (D, Sell), ranked against the other companies in its sector. Its strongest factor then was Financial Health (3.45), around the middle of its sector; its weakest was Profitability (1.02), among the weakest in its sector. The other factors: Growth 2.28 (below most of its sector); Momentum 2.17 (below most of its sector); Valuation 1.51 (more expensive than most of its sector). The current rating is for members: log in to see it.
At $15.07, Summit Therapeutics Inc. trades at 21.3x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -138.8%, return on invested capital of -145.8% and a free cash flow yield of -4.4%. On the balance sheet: a debt-to-equity ratio of 0.04 and a current ratio of 5.99. Over the past 52 weeks the share price ranged from $12.07 to $29.23, with a beta of -1.24.
Summit Therapeutics Inc. does not currently pay a dividend.
23 Wall Street analyst ratings cover the stock: 15 Buy and 8 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.